Screening for Small-Airway Abnormalities After Recurrent Infections: Clinical Relevance and Evidence-Based Approaches

Abstract

Small-airway abnormalities represent a clinically significant yet often underrecognized consequence of recurrent respiratory infections. Early identification of these abnormalities through systematic screening is critical for preventing progression to chronic lung disease. This review synthesizes recent evidence, discusses epidemiological trends, elucidates pathophysiological mechanisms, and provides practical recommendations based on current guidelines for healthcare professionals. Emphasis is placed on high-risk populations, diagnostic modalities, and the evolving landscape of therapeutic interventions targeting small-airway pathology.

Introduction

Recurrent respiratory infections are a major clinical concern, particularly in pediatric populations, immunocompromised patients, and individuals with underlying respiratory disorders. These infections can lead to persistent or progressive small-airway abnormalities, manifesting as airflow limitation or reactive airway disease. With mounting evidence linking early airway changes to long-term morbidity, there is an increasing imperative to establish robust screening strategies among high-risk cohorts. This review aims to provide a comprehensive, evidence-based overview of the need for, and best practices in, screening for small-airway abnormalities following recurrent infections.

Epidemiology / Disease Burden

Globally, respiratory infections remain among the most common illnesses, with acute lower respiratory tract infections causing substantive morbidity, especially in children under five and the elderly. Studies indicate that up to 30% of children with recurrent lower respiratory tract infections exhibit persistent small-airway dysfunction, with a subset progressing to chronic obstructive pulmonary disease (COPD) or asthma later in life. In adults, post-infectious small-airway changes are increasingly recognized as contributors to unexplained dyspnea and early COPD, often preceding radiographic or spirometric abnormalities. The burden is amplified among individuals with impaired immunity, cystic fibrosis, or environmental exposures, underscoring the need for vigilance in these populations.

Pathophysiology

The small airways, defined as bronchioles less than 2 mm in diameter, are particularly susceptible to inflammatory and structural changes following repeated infectious insults. Pathogen-induced epithelial injury, mucous hypersecretion, cytokine-mediated inflammation, and aberrant tissue repair processes collectively drive remodeling, narrowing, and obstruction of these distal airways. Distinct patterns of immune dysregulation—such as persistent neutrophilia, excessive Th2 cytokine release, and impaired mucociliary clearance—can perpetuate a cycle of inflammation and tissue damage. Over time, these mechanisms may culminate in bronchiolitis obliterans, early COPD, or irreversible airflow limitation, even in the absence of classic risk factors like smoking.

Risk Factors

Several risk factors heighten susceptibility to small-airway abnormalities after recurrent infections. These include: young age (particularly infants and young children), genetic predispositions (e.g., alpha-1 antitrypsin deficiency), underlying chronic lung disease (such as asthma or cystic fibrosis), environmental exposures (tobacco smoke, air pollution), immunodeficiencies, and recurrent or severe lower respiratory tract infections, especially those caused by adenovirus, influenza, or respiratory syncytial virus (RSV). Notably, prematurity and neonatal intensive care interventions (e.g., prolonged mechanical ventilation) have been strongly linked to later small-airway dysfunction.

Clinical Features

Small-airway abnormalities often present insidiously and may be clinically silent in early stages. Subtle manifestations include chronic cough, exertional dyspnea, wheezing, and reduced exercise tolerance. Physical examination may reveal fine end-expiratory wheezes or crackles, though these signs are not always present. In advanced cases, patients may develop hypoxemia, overt airflow limitation, or features suggestive of chronic lung disease. Importantly, recurrent infections may themselves be both a cause and a consequence of established small-airway pathology, creating a diagnostic challenge and a potential cycle of disease progression.

Diagnosis

Screening for small-airway abnormalities relies on a combination of clinical assessment and objective testing. Spirometry is the cornerstone, with particular attention to forced expiratory flow at 25–75% of vital capacity (FEF25–75%), which is sensitive to small-airway dysfunction. Impulse oscillometry, nitrogen washout tests, and high-resolution computed tomography (HRCT) provide adjunctive information, especially in cases with inconclusive spirometry. HRCT may reveal mosaic attenuation, air trapping, or bronchial wall thickening. Emerging techniques, such as lung clearance index and advanced imaging modalities, offer promise for earlier detection. Screening is particularly warranted in patients with recurrent infections and unexplained respiratory symptoms, and in those with known risk factors.

Treatment & Management

Management strategies are tailored to the underlying etiology and severity of small-airway involvement. Early intervention focuses on infection prevention (e.g., vaccination, prophylactic antibiotics in select cases), optimizing airway clearance (physiotherapy, mucolytics), and addressing modifiable risk factors (smoking cessation, environmental control). Inhaled corticosteroids and bronchodilators may be beneficial in patients with reversible airflow limitation, though evidence for their efficacy in pure small-airway disease is limited. In severe or progressive cases, immunomodulatory therapy or referral for specialized care (e.g., pediatric pulmonology, transplant evaluation) may be indicated. Multidisciplinary management is essential for optimizing outcomes.

Recent Advances / Emerging Therapies

Recent years have seen advances in both diagnostic and therapeutic approaches for small-airway disease. Novel biomarkers (such as exhaled nitric oxide and volatile organic compounds) are under investigation for noninvasive detection. Biologics targeting specific inflammatory pathways (e.g., anti-IL-5, anti-IgE monoclonal antibodies) have shown promise in selected patients with overlapping allergic phenotypes. In the realm of diagnostics, machine-learning algorithms applied to pulmonary function and imaging data offer potential for earlier, more precise identification of at-risk individuals. These innovations, while promising, require further validation in prospective clinical trials.

Guideline Recommendations

International guidelines, including those from the American Thoracic Society and European Respiratory Society, advocate for proactive screening in high-risk populations, particularly children with recurrent lower respiratory tract infections and individuals with predisposing conditions. Spirometry, supplemented by advanced modalities as indicated, is recommended for baseline and longitudinal assessment. Early multidisciplinary referral is encouraged for patients exhibiting persistent abnormalities. Preventive strategies, such as vaccination and environmental control, are emphasized as cornerstones of care. Guidelines also highlight the importance of clinician awareness and patient education regarding the potential for long-term sequelae after recurrent infections.

Conclusion

Screening for small-airway abnormalities following recurrent infections is a critical, evidence-supported strategy for mitigating the progression to chronic lung disease. Advances in diagnostic technology and an improved understanding of risk factors have enhanced our ability to detect and manage small-airway pathology at earlier stages. Clinicians should maintain a high index of suspicion in at-risk populations and employ guideline-based approaches to diagnosis and management. Ongoing research into biomarkers, advanced imaging, and targeted therapies holds promise for further improving outcomes in this challenging clinical domain.